The Food and Drug Administration has pushed backed its review date for a proposed blockbuster drug to treat lupus from GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI).
The date had been set for Dec. 9.
The review will now take place in March, the companies announced Friday.
HGS said the FDA requested more information after a review by an FDA committee last month. That data has been submitted, the Maryland-based company said.
If approved, the drug could be worth billions of dollars a year in sales.
Read the announcement here.
GSK maintains its U.S. headquarters in Research Triangle Park.
Get the latest news alerts: Follow LTW at Twitter.